J. R. Perez, “Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient Treated with a Novel Combination Treatment with Anti PDL1 Antibody (Durvalumab) and VEGFR2 Antibody (Ramucirumab)”, acmcr, vol. 4, no. 1, pp. 8–14, Jan. 2020.